American Society of Clinical Oncology featured studies on surgical techniques, immunotherapy, weight loss, racial disparities, and international collaboration ahead of the 2023 ASCO annual meeting. The research will be presented at the conference.
A commentary published in the Journal of the National Cancer Institute addresses the issue of cancer equity for people who have been impacted by mass incarceration.
Delays in cancer screening during the COVID-19 pandemic will likely cause a significant increase in cancer cases that could have been caught earlier with screening, and may now be diagnosed at later stages, placing an increased burden on an already strained healthcare system, according to a new research article published in the Journal of the American College of Surgeons.
Researchers from Rice University and Baylor College of Medicine have identified a “glyco-immune” checkpoint inhibitor that could help treat bone cancer metastasis for breast cancer survivors.
Virginia Tech researchers with the Fralin Biomedical Research Institute at VTC have joined a Children’s National Hospital effort to treat deadly brain tumors with ultrahigh frequency sound waves.
A large-scale retrospective analysis by researchers with the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that differences in care, rather than genetics, likely explain disparities in advanced prostate cancer between men of African and European ancestry.
A study, led by researchers at the UCLA Jonsson Comprehensive Cancer Center, found that targeting a metabolic process in people with a specific genetic mutation could help treat glioblastoma.
Patients with cancer whose immune systems are being supported or rebuilt by bone marrow transplantation should begin receiving vaccines for protection against SARS-CoV-2 three months post-transplant, according to a large, prospective, observational study led collaboratively by the Center for International Blood and Marrow Transplant Research, the Blood & Marrow Transplant Clinical Trials Network, and Fred Hutchinson Cancer Center.
Positive high-level results from the FLAURA2 phase III trial showed Tagrisso (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to Tagrisso alone for patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
Interim results from a first-in-human phase I clinical trial evaluating the safety, antitumor activity, and immunological characteristics of a genetically engineered natural killer T-cell immunotherapy for neuroblastoma showed that the treatment was well tolerated. Researchers also observed early evidence of strong antitumor activity.
